HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

KB-R8498

causes vasoconstriction and reduces tumor blood flow

Also Known As:

4-(T-3,T-4-dihydroxycyclopentan-R-1-yl)oxy-2-(1-piperazinyl)quinazoline hydro chloride; KB-R-8498

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - KB-R8498: 2
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - KB-R8498: 2

Experts

1.	Griffin, R J: 1 article (08/2000)
2.	Ogawa, A: 1 article (08/2000)
3.	Song, C W: 1 article (08/2000)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2000 - "There was a growth delay of 14 days when an i.v. injection of KB-R8498 was given and the tumors were heated at 42.5 degrees C either immediately or 1 h later. " 08/01/2000 - "In drug-alone studies, the tumor growth was delayed by 4 days when the drug was infused continuously at a rate of 30-50 mg/kg day(-1) for 7 days or about 2 days when mice were treated with five daily injections of 30 mg/kg KB-R8498." 08/01/2000 - "We have investigated the feasibility of enhancing damage induced by hyperthermia in SCK murine tumors by reducing tumor blood perfusion using a new agent, KB-R8498. "
2.	Hyperthermia 01/01/1999 - "The results suggest that the preferential reduction in tumour blood flow relative to normal tissue blood flow by KB-R8498 may be exploited to enhance the anti-tumour effect of hyperthermia." 01/01/1999 - "Reduction of tumour blood flow with KB-R8498 potentiates the response of tumours to hyperthermia." 08/01/2000 - "We have investigated the feasibility of enhancing damage induced by hyperthermia in SCK murine tumors by reducing tumor blood perfusion using a new agent, KB-R8498. "

Related Therapies and Procedures

1.	Injections